D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral ...

Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of OmniAb in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now ...

Nonfarm payrolls increased by 256,000 jobs last month after rising by a downwardly revised 212,000 in November, while the unemployment rate fell to 4.1% from 4.2%, Reuters reported this morning.

Walgreens Boots Alliance beat analysts' lowered expectations for first-quarter profit and maintained its annual forecast on ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Uniqure N.V. (NASDAQ: QURE) has announced the pricing of its public offering of 4,411,764 ordinary shares at a price of ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...